What exactly are we scaling?
I start with the business that already works. The job is to understand what produced the current result, how much of it belongs to the company, what the next growth move changes, and whether the economics hold once the model meets a new competitive system.
A country is rarely the only thing that changes.
Expansion plans are written by geography: France, Germany, Benelux, the US. The geography matters, and it rarely describes what is changing. The real growth move is often one of these.
Six steps, and what I look at in each.
The work goes deep only where the answer could change the decision. Steps one to five run on public evidence. Step six names the internal data that settles the question.
The home market may be doing more work than it appears.
A business can grow because it has a superior engine. It can also grow because the category is booming, competition is weak or capital is abundant. Those are different starting points for expansion.
If the company moved into another market tomorrow, the parts of the explanation that survive are the parts worth scaling.
A capability can travel and still stop being decisive.
Portability depends on the destination. A capability only matters if the competitive system there rewards it.
A performance-marketing engine may be highly portable, and matter less in a market where pharmacies or specialist advisers control trust and recommendation.
The better market-selection question: what determines winning here, and which part of the existing advantage matters in that system?
Scalable advantage is where capital turns into contribution, EBITDA and cash, and for an owner into the value of the business.
A good market can still be the wrong market for this company.
A where-to-play choice is incomplete until the required how-to-win and the organisational build are visible. Market attractiveness, capability fit and economics have to hold together.
Public evidence finds the right question. Internal data settles it.
Outside-in work can identify strong hypotheses. It cannot replace internal company truth. I keep four classes of evidence apart, in the reviews and in the published cases.
A recommendation should be killable.
A good initiative can still be wrong now. Every material conclusion states the conditions under which it stops being true.
Bring one real expansion decision.
Public evidence first. Then the few internal numbers that settle it.